GlassScriptPhysician profile
Bobbi Tosh
NPI 1104342799
$3,489.21
in general payments reported to CMS, 2019-2025
27 companies · $790 in 2025
The $790 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $307 · 2022: $769 · 2023: $817 · 2024: $807 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,413.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $856.59 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $499.81 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $287.79 | 2022-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $287.26 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $255.10 | 2021-2025 | |
| Abbvie INC. | $226.04 | 2021-2025 | |
| Abbott Laboratories | $196.79 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.00 | 2021-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $119.64 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $62.39 | 2022-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $59.47 | 2022-2023 | |
| Axsome Therapeutics, INC. | $54.00 | 2023 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.78 | 2021-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $50.69 | 2022-2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $46.19 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $45.89 | 2021-2022 | |
| Lundbeck LLC | $35.18 | 2022-2023 | Vyepti |
| Amarin Pharma, INC. | $33.63 | 2021-2022 | |
| Esperion Therapeutics, INC. | $30.00 | 2022-2024 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $26.57 | 2021 | |
| Dexcom, INC. | $25.07 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $18.64 | 2025 | Zoryve |
| Phathom Pharmaceuticals, INC. | $14.59 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $13.22 | 2024 | |
| Scynexis, INC. | $13.04 | 2022 | |
| Ironwood Pharmaceuticals, INC | $12.02 | 2022 | |
| Neurocrine Biosciences, INC. | $11.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bobbi Tosh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.